2019-01-29T16:13:41-07:00 2018-06-30 990 2017-07-01 431266906 PKD Foundation PKDF 8169312600 1001 E 101st Terr Suite 220 Kansas City MO 64131 Russ Petry Controller 8169312600 2018-11-19 75.81.173.130 2017 2019-02-21 02:37:17Z Andy Betts 1001 E 101st Terr Suite 220 Kansas City MO 64131 7304471 0 X www.pkdcure.org X 1982 MO PROMOTE PROGRAMS OF RESEARCH AND EDUCATION TO DISCOVER TREATMENTS AND A CURE FOR POLYCYSTIC KIDNEY DISEASE (PKD). 16 16 46 2400 1485 -249 5881314 5709118 0 0 24748 114587 -37095 -35147 5868967 5788558 1770056 1531349 0 0 2792233 2720408 79200 46142 762604 1988701 1822437 6630190 6120336 -761223 -331778 5695290 5218772 855835 503054 4839455 4715718 X PROMOTE PROGRAMS OF RESEARCH, ADVOCACY, EDUCATION, SUPPORT AND AWARENESS IN ORDER TO DISCOVER TREATMENTS AND A CURE FOR POLYCYSTIC KIDNEY DISEASE AND IMPROVE THE LIVES OF ALL IT AFFECTS. 0 0 2129268 1531349 0 RESEARCH: SINCE ITS FOUNDING IN 1982, THE PKD FOUNDATION HAS INVESTED MORE THAN $43 MILLION IN RESEARCH, CLINICAL AND SCIENTIFIC GRANTS, AS WELL AS FELLOWSHIPS AND SCIENTIFIC MEETINGS, MAKING US THE LARGEST PRIVATE FUNDER OF POLYCYSTIC KIDNEY DISEASE (PKD) RESEARCH. THIS HAS LED TO NEW DISCOVERIES ABOUT PKD, INCLUDING IDENTIFYING THE GENES RESPONSIBLE FOR PKD, WHICH ENABLES RESEARCHERS TO INVESTIGATE POSSIBLE TREATMENTS. THE FOUNDATION HAS A COMPREHENSIVE, INTEGRATED RESEARCH AND DEVELOPMENT PROGRAM THAT REPRESENTS THE CORE OF OUR WORK, AIMED TO SPEED UP DEVELOPMENT OF TREATMENTS WHICH COULD SLOW OR STOP THE PROGRESSION OF PKD. THE FOUNDATION'S FISCAL YEAR INVESTMENTS IN RESEARCH IS OUTLINED BELOW. 1148310 0 6293 EDUCATION AND SUPPORT: THE FOUNDATION PROVIDES LOCAL SERVICES THROUGH ITS MORE THAN 60 VOLUNTEER-RUN CHAPTERS ACROSS THE COUNTRY. THESE VOLUNTEERS BRING TO LIFE THE MISSION OF THE ORGANIZATION BY ENSURING THAT NO ONE FACES THIS DISEASE ALONE. EDUCATION MEETINGS PROVIDE VALUABLE INFORMATION FROM HEALTH CARE PROFESSIONALS, WHILE SUPPORT ACTIVITIES RANGE FROM LENDING A LISTENING EAR TO ORGANIZED GROUP OUTINGS. THIS YEAR ALONE , OUR CHAPTERS HELD l09 EDUCATION AND SUPPORT EVENTS. 1094597 0 0 AWARENESS AND ADVOCACY: THE FOUNDATION RAISES AWARENESS THROUGH MARKETING AND PUBLIC RELATIONS SO PEOPLE KNOW WHAT PKD IS, ABOUT THE FOUNDATION AND HOW TO DONATE. MARKETING MATERIALS INCLUDE PKD PROGRESS MAGAZINE, PKDNEWS MONTHLY EMAIL NEWSLETTER, SOCIAL MEDIA, DISCUSSION FORUMS, BLOGS AND PKDCURE.ORG. VOICES OF PKD (PKDCURE.ORG/VOICESOFPKD) FEATURES TESTIMONIALS AND STORIES ABOUT PEOPLE'S EXPERIENCES WITH THE DISEASE. THERE WAS A SIGNIFICANT INCREASE ON SOCIAL MEDIA, REACHING MORE THAN 40,000 FOLLOWERS INCLUDING FACEBOOK, TWITTER, INSTAGRAM AND YOUTUBE. PKDCURE.ORG RECEIVED 474,800 VISITS, PKD CONNECTION.ORG RECEIVED 79,070 VISIT, WALKFORPKD.ORG RECEIVED 93,347 VISITS. DISCUSSION FORUMS 0 0 0 4372175 1 1 0 1 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 1 1 0 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 18 0 0 46 1 1 1 0 0 0 0 1 1 0 0 0 0 X 16 16 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AK AL AR CA CO CT FL GA HI IL KS KY X X X Russ Petry 8169312600 1001 E 101st Terr Suite 220 Kansas City MO 64131 X Andy Betts CEO 40 X 40333 0 4272 Ray Smith CFO - left July 17 40 X 152860 0 32842 David Baron Chief Scientific Officer 40 X X 200020 0 48109 Angela Connelly Chief Marketing Officer left Dec. 16 40 X X 136700 0 40125 Jamey Rose Director of IT 40 X X 112642 0 27523 642555 0 152871 5 0 1 0 Gabriel Group 3190 Rider Trail S Earth City MO 63045 Fundraising Consultant 139046 1 0 0 289196 0 0 5419922 222314 5709118 0 0 0 0 0 73444 0 0 73444 0 0 0 0 0 0 0 0 0 0 1474514 0 1433371 0 41143 0 41143 0 0 41143 38880 289196 74212 -35332 0 -35332 6293 8330 -2037 -2037 0 0 ADVERTISING 511120 1485 0 1485 0 MISCELLANEOUS 900099 737 0 0 737 0 0 0 0 2222 5788558 -2037 1485 79992 1298194 1298194 113155 113155 120000 120000 0 0 456992 146217 225986 84789 0 0 0 0 1752177 1115136 349335 287706 106466 69302 17926 19238 226100 133057 45885 47158 178673 102915 45692 30066 0 0 0 0 12341 8147 2532 1662 26700 0 26700 0 50000 50000 0 0 46142 46142 15140 15140 222643 128984 16982 76677 11315 11315 218742 116590 75345 26807 95848 57026 24165 14657 0 0 0 0 318872 196521 86382 35969 0 0 0 0 0 0 0 0 680234 586855 30095 63284 0 0 0 0 0 0 0 0 94839 75414 12037 7388 12086 6921 3115 2050 Dues, Fees, Memberships 44092 16841 8240 19011 Research 19585 19585 0 0 0 0 0 0 6120336 4372175 985557 762604 X 6120336 4372175 985557 762604 112888 130705 1888329 1303737 375424 177030 92246 51290 0 0 0 0 0 0 32772 31084 21327 51837 426761 289837 190886 136924 2938227 3316937 0 0 0 0 0 0 43191 19228 5695290 5218772 480346 243087 333333 166667 0 93300 0 0 0 0 0 0 0 0 0 0 42156 0 855835 503054 X 3672367 3553782 167088 161936 1000000 1000000 4839455 4715718 5695290 5218772 -331778 208041 0 0 0 0 X X 0 1 X 1 1 1 X 9195589 6811982 7539923 5881314 5709118 35137926 9195589 6811982 7539923 5881314 5709118 35137926 35137926 1638 2444 7014 31733 73444 116273 1237 129434 10839 30462 39617 211589 35465788 56088 0.99076 0.9366 X Schedule A, Part II, Line 10 MISCELLANEOUS INCOME 2013 AMOUNT: $ 1,237. 2014 AMOUNT: $ 377. 2015 AMOUNT: $ 89. 2016 AMOUNT: $ 162. 2017 AMOUNT: $ 737. GROSS REVENUE FROM FUNDRAISING EVENTS 2014 AMOUNT: $ 129,057. 2015 AMOUNT: $ 10,750. 2016 AMOUNT: $ 30,300. 2017 AMOUNT: $ 38,880. 0 0 0 0 0 0 0 0 0 0 0 2773007 0 310566 0 108000 15140 2960433 0 2700000 77487 0 0 4480 2773007 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.651 0.3378 0.0112 0 0 0 0 0 0 0 0 0 0 0 0 0 0 426761 289837 136924 0 0 0 0 136924 0 0 X 6424607 208041 434818 0 8330 651189 5773418 15140 0 15140 5788558 6548344 434818 0 0 8330 443148 6105196 15140 0 15140 6120336 Schedule D, Part V, Line 4 THE PURPOSE OF THE RESEARCH OPPORTUNITY FUND AND NAMED ENDOWMENTS (COLLECTIVELY REFERRED TO AS "ENDOWMENTS") IS TO PROVIDE FOR GROWTH-ORIENTED LONG-TERM INVESTMENT OF FUNDS THAT ARE NOT NEEDED TO MEET THE DAY-TO-DAY FINANCIAL OBLIGATIONS OF THE FOUNDATION. Schedule D, Part X, Line 2 THE FOUNDATION IS EXEMPT FROM INCOME TAXES UNDER SECTION 501(C)(3) OF THE U.S. INTERNAL REVENUE CODE. THE FOUNDATION DOES NOT OPERATE AS A PRIVATE FOUNDATION. ALTHOUGH IT IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES ON ITS PRINCIPAL OPERATIONS, THE FOUNDATION IS SUBJECT TO FEDERAL INCOME TAXES ON THE NET INCOME FROM ANY OPERATIONS IDENTIFIED BY THE INTERNAL REVENUE SERVICE TO GENERATE UNRELATED BUSINESS INCOME. NO SUCH UNRELATED BUSINESS INCOME TAX WAS INCURRED DURING 2017 OR 2016. THE FOUNDATION FOLLOWS THE STANDARDS FOR EVALUATING UNCERTAIN TAX POSITIONS AND HAS DETERMINED NO LIABILITY SHOULD BE RECORDED FOR UNCERTAIN TAX POSITIONS. Schedule D, Part XI, Line 2d OTHER ADJUSTMENTS: COST OF GOODS SOLD FOR MERCHANDISE SALES 8,330. Schedule D, Part XII, Line 2d OTHER ADJUSTMENTS: COST OF GOODS SOLD FOR MERCHANDISE SALES 8,330. 0 Europe (including Iceland and Greenland) 0 0 Grantmaking EXPENDITURES ARE REPORTED AT THE AMOUNT OF THE GRANT AWARDED AND ARE ACCOUNTED FOR USING THE SAME METHOD IN THE ORGANIZATION'S FINANCIAL STATEMENTS. 80000 North America (including Canada and Mexico, but not the United States) 0 0 Grantmaking EXPENDITURES ARE REPORTED AT THE AMOUNT OF THE GRANT AWARDED AND ARE ACCOUNTED FOR USING THE SAME METHOD IN THE ORGANIZATION'S FINANCIAL STATEMENTS. 40000 0 0 120000 Europe (including Iceland and Greenland) RESEARCH THE ROLE OF AUTOPHAGY IN RENAL CYSTOGENESIS 80000 ACH TRANSFER 0 BOOK North America (including Canada and Mexico, but not the United States) GENETIC MODIFIERS OF SEVERE POLYCYSTIC LIVER DISEASE RESEARCH 40000 ACH TRANSFER 0 BOOK 2 0 0 0 0 0 0 0 Schedule F, Part I, Line 2 ALL GRANTEES ARE REQUIRED TO SUBMIT AN ANNUAL RESEARCH PROGRESS REPORT AND AN ANNUAL INSTITUTIONAL FINANCIAL STATUS REPORT. MOST GRANTEES ARE ALSO REQUIRED TO SUBMIT INTERIM QUARTERLY PROGRESS REPORTS. Schedule F, Part I, Line 3 EXPENDITURES ARE REPORTED AT THE AMOUNT OF THE GRANT AWARDED AND ARE ACCOUNTED FOR USING THE SAME METHOD IN THE ORGANIZATION'S FINANCIAL STATEMENTS. X X X X X X 1 GABRIEL GROUP 3190 RIDER TRAIL SOUTH EARTH CITY MO 63045 CREATE, PRINT AND SEND DIRECT MAIL CONTRIBUTION 0 1090954 46142 1044812 1090954 46142 1044812 AK AL AR CA CO CT FL GA HI IL KS KY MA MD ME MI MN MS NC ND NH NJ NM NV NY OH OK OR PA RI SC TN UT VA WA WI WV GRATITUDE BENEFIT 328076 289196 38880 0 630 7373 36677 0 29832 0 0 328076 289196 38880 0 630 7373 36677 0 29832 74512 -35632 Schedule G, Part I, Line 2b (I) NAME OF FUNDRAISER: GABRIEL GROUP (I) ADDRESS OF FUNDRAISER: 3190 RIDER TRAIL SOUTH, EARTH CITY, MO 63045 (II) ACTIVITY: CREATE, PRINT AND SEND DIRECT MAIL CONTRIBUTION SOLICITATION Schedule G, Part I, Line 2b(v) PAID PROFESSIONAL FUNDRAISER TO CREATE, PRINT AND SEND DIRECT MAIL CONTRIBUTION SOLICITATIONS. PAYMENTS WERE MADE BY CHECK. 1 CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVE NORD HALL CLEVELAND OH 44106 311018992 501(C)(3) 80000 0 RESEARCH ON MAGNETIC RESONANCE FINGERPRINTING (MRF) TO ASSESS ARPKD KIDNEY AND LIVER DISEASE. FASEB 9651 ROCKVILLE PIKE BETHESDA MD 20814 520700497 501(C)(3) 33000 2017 FASEB SCIENCE RESEARCH CONFERENCE ON PKD (18,000) AND RESEARCH ON THE BIOLOGY CILIE KU MEDICAL CENTER ENDOWMENT 3901 RAINBOW BLVD KANSAS CITY KS 66160 480547734 501(C)(3) 10000 GRANTHAM SYMPOSIUM SPONSORSHIP MAYO CLINIC 200 FIRST ST SW PLUMMER 5 ROCHESTER MN 55905 416011702 501(C)(3) 220000 RESEARCH ON ADPKD GENE MUTATION REGISTRY (40,000) PKD MUTATION GENETIC DATABASE SUPPORT NEW YORK UNIVERSITY 25 WEST 4TH ST 4TH FLR NEW YORK NY 10012 135562308 5Ol( C ) ( 3 ) 80000 RESEARCH A NOVEL SCREEN TO IDENTIFY KINASES THAT ARE ACTIVATED IN PKD KIDNEYS SEATTLE CHILDREN'S HOSPITAL PO BOX 5371 MS S-200 SEATTLE WA 98145 910564748 501(C)(3) 80000 RESEARCH ON SCREENING FOR MODIFIERS OF PKD SEVERITY USING ENU MUTAGENESIS UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVE S AB-1230 BIRMINGHAM AL 35294 636005396 501(C)(3) 160000 RESEARCH ON INJURY RESPONSE MEDIATED PATHOGENESIS IN CILIOPATHIES (80,000) AND UNIVERSITY OF COLORADO PO BOX 910439 DENVER CO 80921 846000555 GOV 50000 RESEARCH ON PKD GENE THERAPY TARGETING THE 4E-BP1 PATHWAY UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE 4330 SHAWNEE MISSION PKWY FAIRWAY KS 66205 481108830 501(C)(3) 205000 RESEARCH ON TARGETING THE LKB1-AMPK SIGNALING PATHWAY IN POLYCYSTIC KIDNEY DISEASE (50,000), UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE 655 W BALTIMORE S BALTIMORE MD 21201 526002033 GOV 80000 RESEARCH ON THE ROLE - FIBROCYSTIN/POLYDUCTIN IN HEALTH AND ARPKD (80,000) UNIVERSITY OF WASHINGTON PO BOX 359505 SEATTLE WA 98195 916001537 GOV 80000 RESEARCH ON MODELING HUMAN PKD CYSTOGENESIS WITH PLURIPOTENT STEM CELLS YALE UNIVERSITY PO BOX 1872 NEW HAVEN CT 06508 060646973 501(C)(3) 210000 RESEARCH ON EXAMINING THE ROLE OF XBP1 IN THE PATHOGENESIS OF PROTEIN FOLDING-ASSOCIATED 14 0 RESEARCH 2 113155 0 Schedule I, Part I, Line 2 ALL GRANTEES ARE REQUIRED TO SUBMIT AN ANNUAL RESEARCH PROGRESS REPORT AND AN ANNUAL INSTITUTIONAL FINANCIAL STATUS REPORT. MOST GRANTEES ARE ALSO REQUIRED TO SUBMIT INTERIM QUARTERLY PROGRESS REPORTS. Schedule I, Part II, Line 1 COLUMN (H): NAME OF ORGANIZATION OR GOVERNMENT: CASE WESTERN RESERVE UNIVERSITY (H) PURPOSE OF GRANT OR ASSISTANCE: RESEARCH ON MAGNETIC RESONANCE FINGERPRINTING (MRF) TO ASSESS ARPKD KIDNEY AND LIVER DISEASE PROGRESSION X X X X 1 0 0 0 0 0 0 0 0 Ray Smith CFO - left July 17 139838 0 13022 0 0 0 11620 0 21222 0 185702 0 0 0 David Baron Chief Scientific Officer 181300 0 18720 0 0 0 24000 0 24109 0 248129 0 0 0 Angela Connelly Chief Marketing Officer left Dec. 16 108705 0 10631 0 17364 0 10579 0 29546 0 176825 0 0 0 Schedule J, Part I, Line 4 (1) HANCOCK JR., JACKIE (i)196,004. (ii)31,500 (iii)8,125. (C)14,550 (D)35,015 (E)285,194 CEO:LEFT OCT 16 (2) SMITH, RAY (i)139,838 (ii)13,022. (C)11,620 (D)21,222 (E)185,702 CFO:LEFT JUL 17 (3) BARON, DAVID (i)181,300 (ii)18,720 (C)24,000 (D)24,109 (E)248,129 CHIEF SCIENTIFIC OFFICER (4) CONNELLY, ANGELA (i)108,705 (ii)10,631 (iii)17,364 (C)10,579 (D)29,546 (E)176,825 CHIEF MARKETING OFFICER:LEFT DEC 16 X 14 166249 FAIR VALUE X EVENT ITEMS 374 56065 FAIR VALUE 1 0 1 1 Schedule M, Part I COLUMN (B): FIGURE REPRESENTS THE NUMBER OF DONORS. Schedule M, Part I, Line 32b ORGANIZATION UTILIZES ONGOING BANKING RELATIONSHIPS TO MARKET DONATED SECURITIES. Form 990, Part III, Line 4a PROGRAM SERVICE ACCOMPLISHMENTS: RESEARCH GRANTS: INVESTED $1,105,000 ON GRANT FUNDING TO 15 PKD PROJECTS THAT FOCUS ON THE DEVELOPMENT OF A TREATMENT FOR PKD OR ON UNDERSTANDING THE WAY IN WHICH CYSTS DEVELOP OR ENLARGE IN PKD. FELLOWSHIPS: PROVIDED $200,000 IN FELLOWSHIP FUNDING TO 4 PKD PROJECTS. CORE GRANTS: INVESTED $60,000 TO SUPPORT CORE RESEARCH GRANTS SERVICES AND RESOURCES FOR PKD SCIENTISTS IN TWO CORE LABS SO THAT FOUNDATION DOLLARS CAN BE LEVERAGED ACROSS THE PKD RESEARCH COMMUNITY. SCIENTIFIC MEETINGS: INVESTED $53,000 TO FUND PKD-RELATED MEETINGS THAT BRING EXPERTS TOGETHER AND PROVIDE CONTINUING EDUCATION FOR HEALTH PROFESSIONALS. Form 990, Part III, Line 4b PROGRAM SERVICE ACCOMPLISHMENTS: HELD THIS YEAR THAT RAISED $469,170. CHAPTERS ALSO RAISE AWARENESS AND MONEY THROUGH THE WALK FOR PKD, THE FOUNDATION'S SIGNATURE FUNDRAISING AND PUBLIC AWARENESS EVENT. THE WALK TAKES PLACE IN MORE THAN 50 CITIES ACROSS THE NATION EACH YEAR AND HAS RAISED NEARLY $28 MILLION SINCE 2000. ON A NATIONAL LEVEL, THE FOUNDATION PROVIDES IN-DEPTH RESOURCES AND EDUCATION ABOUT LIVING WITH PKD TO EMPOWER PEOPLE TO MANAGE THEIR HEALTH. OFFERINGS INCLUDE WEBINARS, VIDEOS, A MULTI-FACETED WEBSITE (PKDCURE.ORG/LEARN), ONLINE COMMUNITIES AND PRINT MATERIALS. ADDITIONALLY, 10 WEBINARS WERE ATTENDED OR VIEWED BY MORE THAN 819 PEOPLE. THE PKD PATIENT HANDBOOK IS AVAILABLE FOR PEOPLE WITH ADPKD TO HELP THEM NAVIGATE THEIR DISEASE. IT WAS SENT TO 731 PEOPLE LAST YEAR. Form 990, Part III, Line 4c PROGRAM SERVICE ACCOMPLISHMENTS: RECEIVED 17,579 VISITS AND THREE ISSUES OF PKD PROGRESS WERE SENT TO MORE THAN 20,000 MEMBERS OF THE PKD COMMUNITY. THE FOUNDATION PLAYS A KEY ROLE IN LEGISLATIVE ADVOCACY TO SUPPORT PKD-RELATED INITIATIVES. THE PKD ADVOCACY ACTION CENTER (PKDCURE.ORG/ADVOCATE) SENT ADVOCACY ALERTS TO 8,453 PEOPLE ABOUT LEGISLATIVE AND PUBLIC POLICY ISSUES IMPACTING PKD PATIENTS AND FAMILIES. THE FOUNDATION JOINS WITH OTHER KIDNEY DISEASE-RELATED ORGANIZATIONS IN EVENTS THAT ALLOW ADVOCATES TO MEET WITH MEMBERS OF CONGRESS TO RAISE AWARENESS OF PKD AND DISCUSS LEGISLATIVE PRIORITIES. PKD FOUNDATION STAFF MEMBERS AND PATIENTS ATTENDED THREE EVENTS IN WASHINGTON, D.C. Form 990, Part VI, Section B, Line 11b THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. PRIOR TO FILING THE FORM 990 FOR PKD FOUNDATION, A DRAFT COPY WILL BE PROVIDED TO THE BOARD OF TRUSTEES FOR REVIEW AND COMMENT. ANY COMMENTS WILL BE ACCUMULATED BY MANAGEMENT AND ADDRESSED ACCORDINGLY PRIOR TO FILING WITH THE IRS. MEMBERS OF THE BOARD OF TRUSTEES OF PKD FOUNDATION ARE REQUIRED TO SIGN AN ANNUAL STATEMENT DISCLOSING ANY CONFLICTS OF INTEREST. THE GOVERNANCE COMMITTEE REVIEWS THE STATEMENTS AND ENSURES THAT BOARD MEMBERS ARE PROHIBITED FROM PARTICIPATING IN DISCUSSIONS OR DECISIONS RELATED TO TRANSACTIONS THAT INVOLVE ACTUAL CONFLICTS OF INTEREST. Form 990, Part VI, Section B, Line 12c MEMBERS OF THE BOARD OF TRUSTEES OF PKD FOUNDATION ARE REQUIRED TO SIGN AN ANNUAL STATEMENT DISCLOSING ANY CONFLICTS OF INTEREST. THE GOVERNANCE COMMITTEE REVIEWS THE STATEMENTS AND ENSURES THAT BOARD MEMBERS ARE PROHIBITED FROM PARTICIPATING IN DISCUSSIONS OR DECISIONS RELATED TO TRANSACTIONS THAT INVOLVE ACTUAL CONFLICTS OF INTEREST. Form 990, Part VI, Section B, Line 15 ANNUALLY, THE CHAIRMAN OF THE BOARD OF TRUSTEES WORKS WITH THE CEO TO DEVELOP THE CEO'S GOALS FOR THE NEW FISCAL YEAR. AT THE END OF EACH FISCAL YEAR, THE EXECUTIVE COMMITTEE EVALUATES THE CEO AGAINST THESE GOALS AND RECOMMENDS TO THE BOARD THE CEO'S COMPENSATION PACKAGE FOR APPROVAL, BASED ON THIS EVALUATION. ANNUALLY, THE EXECUTIVE COMMITTEE REVIEWS A NATIONAL SALARY SURVEY CONDUCTED BY AN INDEPENDENT CONSULTANT. UPON THAT REVIEW, SALARIES ARE COMPARED TO THE RANGES RECOMMENDED FOR EACH POSITION. FOUNDATION MANAGEMENT THEN ACTS TO ENSURE THAT SALARIES ARE WITHIN APPROPRIATE RANGES. Form 990, Part VI, Section C, Line 17 LIST OF STATES RECEIVING COPY OF FORM 990: AK,AL,AR,CA,CO,CT,FL,GA,HI,IL,KS,KY,MA,MD,ME,MI,MN,MS,NC,ND,NH,NJ,NM,NV,NY OH,OK,OR,PA,RI,SC,TN,UT,VA,WA,WI,WV Form 990, Part VI, Section C, Line 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON THEIR OWN WEBSITE AND UPON REQUEST. Form 990, Part VII, Section A, Line 1a PKD FOUNDATION CONTRACTS WITH ADP TOTALSOURCE TO PROVIDE CERTAIN EMPLOYEE BENEFITS AND PAYROLL SERVICES. EMPLOYEES ARE CONSIDERED TO BE JOINTLY EMPLOYED BY BOTH PKD FOUNDATION AND ADP TOTALSOURCE. IN ORDER TO COMPLY WITH TRANSPARENCY DIRECTIVES AS A PART OF THE FORM 990, THE FOUNDATION HAS DECIDED TO REPORT COMPENSATION IN PART VII TO INCLUDE AMOUNTS PAID AND REPORTED ON W-2'S BY ADP TOTALSOURCE. Form 990, Part XII, Line 2c NO CHANGE FROM THE PRIOR YEAR. PKD Foundation's fiscal year ended June 30, 2018. We are still waiting on approval of final audited financial statements.